Olverembatinib for FGFR1-rearranged Neoplasms

This study is testing a drug called olverembatinib in patients with a rare type of blood cancer (myeloid or lymphoid neoplasms) that is caused by a rearrangement in the FGFR1 gene, which is very hard to treat with standard chemotherapy. **You may be eligible if...** - You have newly diagnosed, progressed, or relapsed myeloid or lymphoid neoplasm with FGFR1 gene rearrangement - Your overall health is good enough for treatment (ECOG 0–3 for myeloproliferative neoplasms, or 0–2 for acute leukemia) - Your expected survival is at least 12 weeks - You are able and willing to follow study procedures and visits **You may NOT be eligible if...** - You have previously received an allogeneic stem cell transplant or the drug ponatinib - You have HIV, active hepatitis B, or active hepatitis C - You are pregnant, planning to become pregnant, or breastfeeding - You have conditions that would compromise your safety in the study Talk to your doctor to see if this trial is right for you.